Companies/COSCIENS Biopharma Inc.

Company profile

COSCIENS Biopharma Inc.

OTC: CSCIF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Toronto, ONReports USD

#658 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

43D

FH 45DQ —GM 30SS 58

v0.1 · 45/100 weight · provisional

↑ listing tenure, Piotroski F · ↓ return on equity, revenue growth (YoY)

Methodology →

Revenue TTM

$7.9M

Rev growth YoY (TTM)

-11.6%

Net income (FY)

-$10.5M

Employees

Market cap

$7.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$7.6M$7.6M2025

Net income-$10.5M-$10.5M2025

Operating income-$10.6M-$10.6M2025

Total assets$21.4M$21.4M2025

Liabilities$17.5M$17.5M2025

Equity$3.8M$3.8M2025

Revenue trend

FY2018 – FY2025 · USD

$6.6M

FY18

$7.4M

FY19

$3.5M

FY20

$5.3M

FY21

$11.2M

FY22

$5.3M

FY23

$13.8M

FY24

$7.6M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

COSCIENS Biopharma Inc. booked $7.6M in FY2025 revenue, contracting 45% year over year — slower than 80% of Healthcare companies we track, at a -138.1% net margin.

Peers · Healthcare

Bolt Biotherapeutics, Inc.39D CEL-SCI Corporation32D NKGen Biotech, Inc.——OSR Holdings, Inc.33D

Key facts

CEOPeter Harry Puccetti

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersToronto, ON

ExchangeOTC: CSCIF

Employees28

IPO date2000-05-10

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.